Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 10/2015

01-10-2015 | Original Article - Observational Research

Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults

Authors: Muharrem Cidem, Ilhan Karacan, Neval Bozok Arat, Oguzhan Zengi, Murat Ozkaya, Saadet Pilten Guzel, Cansu Ozkan, Ozan Beytemur

Published in: Rheumatology International | Issue 10/2015

Login to get access

Abstract

Sclerostin is produced almost exclusively by osteocytes, which also express receptors for 1,25 dihydroxyvitamin D3. The aim of this study was to investigate the effects of vitamin D3 treatment on serum sclerostin levels in young adult females with severe vitamin D deficiency. A total of 26 subjects were treated orally with calcium (1.200 mg/day for 2 months) and vitamin D3 (300.000 IU/week for 1 month). Serum 25-hydroxyvitamin D (25(OH)D) and sclerostin levels were measured before and after treatment. Baseline serum 25(OH)D and sclerostin levels were at 5.7 ± 2.4 ng/mL and 39.1 ± 14.4 pg/mL, respectively. Serum 25(OH)D was significantly increased, to 62.4 ± 18.7 ng/mL, following treatment; serum sclerostin was significantly decreased, to 29.3 ± 8.8 pg/mL. We conclude that serum sclerostin level is decreased following vitamin D3 treatment in patients with vitamin D deficiency.
Literature
1.
Girgis CM, Clifton-Bligh RJ, Turner N, Lau SL, Gunton JE (2014) Effects of vitamin D in skeletal muscle: falls, strength, athletic performance and insulin sensitivity. Clin Endocrinol (Oxf) 80:169–181. doi:10.​1111/​cen.​12368 CrossRef
2.
3.
Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253. doi:10.​1210/​jc.​2010-0067 CrossRefPubMed
4.
Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875CrossRefPubMed
5.
Lombardi G, Lanteri P, Colombini A, Mariotti M, Banfi G (2012) Sclerostin concentrations in athletes: role of load and gender. J Biol Regul Homeost Agents 26(1):157–163PubMed
6.
van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327CrossRefPubMed
7.
Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997PubMedCentralCrossRefPubMed
8.
9.
10.
11.
Cidem M, Usta TA, Karacan I, Kucuk SH, Uludag M, Gun K (2013) Effects of sex steroids on serum sclerostin levels during the menstrual cycle. Gynecol Obstet Invest 75:179–184. doi:10.​1159/​000347013 CrossRefPubMed
12.
13.
14.
Burger EH, Klein-Nulend J (1999) Mechanotransduction in bone–role of the lacuno-canalicular network. FASEB J 13(Suppl):S101–S112PubMed
15.
16.
Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BE (2008) Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 23(11):1859–1863. doi:10.​1359/​jbmr.​080607 CrossRefPubMed
Metadata
Title
Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults
Authors
Muharrem Cidem
Ilhan Karacan
Neval Bozok Arat
Oguzhan Zengi
Murat Ozkaya
Saadet Pilten Guzel
Cansu Ozkan
Ozan Beytemur
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3294-1

Other articles of this Issue 10/2015

Rheumatology International 10/2015 Go to the issue

Original Article - Cases with a Message

Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end

Review Article - Outcomes Research

Behaviour change interventions to promote physical activity in rheumatoid arthritis: a systematic review

Case Based Review - Cases with a Message

Behçet’s disease and comorbidity: internal case reports and literature review

Short Communication - Pathology Reviews

Semaphorin 3A: an immunoregulator in systemic sclerosis

Original Article - Observational Research

Pediatric-onset Takayasu’s arteritis: clinical features and short-term outcome

Original Article - Observational Research

Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits